DelveInsight’s “Dermatomyositis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dermatomyositis, historical and forecasted epidemiology as well as the Dermatomyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dermatomyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dermatomyositis Market Forecast

Some of the key facts of the Dermatomyositis Market Report: 

• The Dermatomyositis market size was valued approximately USD 230 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

• As per DelveInsight’s projections, within the 7MM, the United States dominated the dermatomyositis market, generating approximately USD 139.3 million in revenue in 2022. Subsequently, Japan, Germany, the UK, and other regions followed suit.

• DelveInsight’s projections suggest that in 2022, approximately 71,351 cases of diagnosed prevalent dermatomyositis were recorded across the 7MM. Among these cases, around 9% were juvenile while the remaining 91% were adult. Over the study period from 2019 to 2032, it is anticipated that these numbers will rise, indicating a growing prevalence of the condition by 2032.

• In 2022, the United States contributed to roughly 54% of the total diagnosed prevalent cases of dermatomyositis among the 7MM. Meanwhile, the European Union’s four major countries and the United Kingdom together accounted for nearly 29%, and Japan represented approximately 17%. Projections indicate an expected increase in these cases by 2032.

• The annual incidence of adult dermatomyositis is pegged at 1.9 and 7.7/1,000,000, according to Orphanet et al. (n.d.). Juvenile dermatomyositis (JDM) affects 1 in 50,000 to 1 in 500,000 children under the age of 18

• The present developing pipeline for dermatomyositis shows significant promise, with notable candidates such as Priovant Therapeutics/Pfizer’s brepocitinib (PF06700841), CSL Behring’s HIZENTRA (IgPro20), AstraZeneca’s ULTOMIRIS (ravulizumab/ALXN1210), Argenx’s efgartigimod, Pfizer’s PF-06823859 (dazukibart), and several others.

• Dermatomyositis Intravenous Immune Globulin TrialIn the 16-week ProDERM Trial Group study of adults with dermatomyositis, the proportion of patients who responded with at least a modest improvement based on a composite score of disease activity was considerably higher in the IVIG group than in the placebo group. Thromboembolism and adverse outcomes were linked to IVIG

• In the year 2023, Treatment of juvenile dermatomyositis with abatacept therapy shows promising results. A significant portion of individuals with juvenile dermatomyositis, an uncommon but frequently severe and chronic systemic autoimmune disease, are resistant to treatment and require long-term immunosuppressive therapy. The use of the targeted biologic medication abatacept to treat these individuals has shown potential in a small open-label research that was published in Arthritis and Rheumatology

• Lenabasum, a CB2 agonist that causes inflammation to subside, has been successfully used to treat amyopathic dermatomyositis, according to a recent study published in the Journal of Investigative Dermatology

• Key Dermatomyositis Companies: AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals, Holdings, Inc., Ermium Therapeutics, Kezar Life Sciences Inc., Néovacs, Horizon Therapeutics plc, Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, Alexion, Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Galapagos NV, EMD Serono, Pfizer, Octapharma, Kezar Life Sciences, Inc., Japan Blood Products Organization, Mallinckrodt, Genentech, Inc., Astellas Pharma Inc, Biogen, and others

• Key Dermatomyositis Therapies: Brepocitinib, Lenabasum, HIZENTRA, Ravulizumab, Lenabasum, IMO-8400, GLPG3667, M5049, PF-06823859, Octagam, KZR-616, GB-0998, H.P. Acthar Gel, Adrenocorticotropic Hormone Gel, tocilizumab, Tacrolimus, Rituximab, and others

• The Dermatomyositis epidemiology based on gender analyzed that dermatomyositis is more common in women than in men (2:1)

• The Dermatomyositis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dermatomyositis pipeline products will significantly revolutionize the Dermatomyositis market dynamics.

Dermatomyositis Overview

Dermatomyositis is a rare autoimmune disease characterized by inflammation of the muscles and skin. It causes muscle weakness and a distinctive skin rash, typically affecting the face, neck, shoulders, upper chest, elbows, knees, and knuckles. The exact cause is unknown, but it’s believed to involve a combination of genetic predisposition, environmental factors, and an abnormal immune response. 

Get a Free sample for the Dermatomyositis Market Report:

https://www.delveinsight.com/report-store/dermatomyositis-market

Dermatomyositis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dermatomyositis Epidemiology Segmentation:

The Dermatomyositis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Dermatomyositis

• Prevalent Cases of Dermatomyositis by severity

• Gender-specific Prevalence of Dermatomyositis

• Diagnosed Cases of Episodic and Chronic Dermatomyositis

Download the report to understand which factors are driving Dermatomyositis epidemiology trends @ Dermatomyositis Epidemiology Forecast

Dermatomyositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dermatomyositis market or expected to get launched during the study period. The analysis covers Dermatomyositis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dermatomyositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dermatomyositis Therapies and Key Companies

• Brepocitinib: Priovant Therapeutics, Inc.

• Lenabasum: Corbus Pharmaceuticals

• HIZENTRA: CSL Behring

• Ravulizumab: Alexion

• Lenabasum: Corbus Pharmaceuticals Inc.

• IMO-8400: Idera Pharmaceuticals

• GLPG3667: Galapagos NV

• M5049: EMD Serono

• human immunoglobulin G: CSL Behring

• PF-06823859: Pfizer

• Octagam: Octapharma

• KZR-616: Kezar Life Sciences, Inc.

• GB-0998: Japan Blood Products Organization

• H.P. Acthar Gel: Mallinckrodt

• Adrenocorticotropic Hormone Gel: Mallinckrodt

• tocilizumab: Genentech, Inc.

• Tacrolimus: Astellas Pharma Inc

• Rituximab: Biogen

Discover more about therapies set to grab major Dermatomyositis market share @ Dermatomyositis Treatment Market

Dermatomyositis Market Strengths

• A significant increase in knowledge and understanding of disease pathogenesis has led to the identification of various novel MoAstargeting C5 complement, IFNβ1, FcRn, and others. 

• Established diagnostic and clinical guidelines for adult and juvenile dermatomyositis enable informed treatment and management of patients

Dermatomyositis Market Opportunities

• Better prognostic markers would allow physicians to diagnose and begin treatment at early onset, possibly preventing disease progression. 

• The lack of curative and effective therapies allows pharma players to conduct trials and bring novel, disease-modifying therapies.

Scope of the Dermatomyositis Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Dermatomyositis Companies: AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals, Holdings, Inc., Ermium Therapeutics, Kezar Life Sciences Inc., Néovacs, Horizon Therapeutics plc, Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, Alexion, Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Galapagos NV, EMD Serono, Pfizer, Octapharma, Kezar Life Sciences, Inc., Japan Blood Products Organization, Mallinckrodt, Genentech, Inc., Astellas Pharma Inc, Biogen, and others

• Key Dermatomyositis Therapies: Brepocitinib, Lenabasum, HIZENTRA, Ravulizumab, Lenabasum, IMO-8400, GLPG3667, M5049, PF-06823859, Octagam, KZR-616, GB-0998, H.P. Acthar Gel, Adrenocorticotropic Hormone Gel, tocilizumab, Tacrolimus, Rituximab, and others

• Dermatomyositis Therapeutic Assessment: Dermatomyositis current marketed and Dermatomyositis emerging therapies

• Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Dermatomyositis Unmet Needs, KOL’s views, Analyst’s views, Dermatomyositis Market Access and Reimbursement 

To know more about Dermatomyositis companies working in the treatment market, visit @ Dermatomyositis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Dermatomyositis Market Report Introduction

2. Executive Summary for Dermatomyositis

3. SWOT analysis of Dermatomyositis

4. Dermatomyositis Patient Share (%) Overview at a Glance

5. Dermatomyositis Market Overview at a Glance

6. Dermatomyositis Disease Background and Overview

7. Dermatomyositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Dermatomyositis 

9. Dermatomyositis Current Treatment and Medical Practices

10. Dermatomyositis Unmet Needs

11. Dermatomyositis Emerging Therapies

12. Dermatomyositis Market Outlook

13. Country-Wise Dermatomyositis Market Analysis (2019–2032)

14. Dermatomyositis Market Access and Reimbursement of Therapies

15. Dermatomyositis Market Drivers

16. Dermatomyositis Market Barriers

17.  Dermatomyositis Appendix

18. Dermatomyositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/